The susceptibility of the reproductive system to early exposure to steroid hormones has become a major concern in our modern societies. Human fetuses are at risk of abnormal programming via exposure to endocrine disrupting chemicals, inadvertent use of contraceptive pills during pregnancy, as well as from excess exposure to steroids due to disease states. Animal models provide an unparalleled resource to understand the developmental origin of diseases. In female sheep, prenatal exposure to testosterone excess results in an array of adult reproductive disorders that recapitulate those seen in women with polycystic ovary syndrome (PCOS), including disrupted neuroendocrine feedback mechanisms, increased pituitary sensitivity to gonadotropin-releasing hormone, luteinizing hormone excess, functional hyperandrogenism, and multifollicular ovarian morphology culminating in early reproductive failure. Prenatal testosterone treatment also leads to fetal growth retardation, insulin resistance, and hypertension. Mounting evidence suggests that developmental exposure to an improper steroidal/metabolic environment may mediate the programming of adult disorders in prenatal testosterone-treated females, and these defects are maintained or amplified by the postnatal sex steroid and metabolic milieu. This review addresses the steroidal and metabolic contributions to the development and maintenance of the PCOS phenotype in the prenatal testosterone-treated sheep model, including the effects of prenatal and postnatal treatment with an androgen antagonist or insulin sensitizer as potential strategies to prevent/ameliorate these dysfunctions. Insights obtained from these intervention strategies on the mechanisms underlying these defects are likely to have translational relevance to human PCOS.

Keywords:
Androgens, Estrogens, Insulin, Fertility, Polycystic ovary syndrome
1.
Barker DJ: The developmental origins of adult disease. J Am Coll Nutr 2004;23:588-595.
2.
Fowden AL, Giussani DA, Forhead AJ: Intrauterine programming of physiological systems: causes and consequences. Physiology 2006;21:29-37.
3.
Aceti A, Santhakumaran S, Logan KM, Philipps LH, Prior E, Gale C, Hyde MJ, Modi N: The diabetic pregnancy and offspring blood pressure in childhood: a systematic review and meta-analysis. Diabetologia 2012;55:3114-3127.
4.
Poston L: Developmental programming and diabetes - the human experience and insight from animal models. Best Pract Res Clin Endocrinol Metab 2010;24:541-552.
5.
Nathanielsz PW, Poston L, Taylor PD: In utero exposure to maternal obesity and diabetes: animal models that identify and characterize implications for future health. Clin Perinatol 2007;34:515-526.
6.
Markey CM, Coombs MA, Sonnenschein C, Soto AM: Mammalian development in a changing environment: exposure to endocrine disruptors reveals the developmental plasticity of steroidhormone target organs. Evol Dev 2003;5:67-75.
7.
McEwen B: Steroid hormones: effect on brain development and function. Horm Res Paediatr 1992;37:1-10.
8.
Padmanabhan V, Veiga-Lopez A: Animal models of the polycystic ovary syndrome phenotype. Steroids 2013;78:734-740.
9.
Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC: Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009;30:293-342.
10.
Jost A, Vigier B, Prepin J, Perchellet JP: Studies on sex differentiation in mammals. Recent Prog Horm Res 1973;29:1-41.
11.
Gorski RA: Sexual differentiation of the brain: a model for drug-induced alterations of the reproductive system. Environ Health Perspect 1986;70:163-175.
12.
Short R: Sexual differentiation of the brain of the sheep. J Endocrinol 1975;66:5P.
13.
Manikkam M, Steckler TL, Welch KB, Inskeep EK, Padmanabhan V: Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects. Partial restoration of ovarian function by cyclic progesterone treatment. Endocrinology 2006;147:1997-2007.
14.
Clarke I, Scaramuzzi R, Short R: Ovulation in prenatally androgenized ewes. J Endocrinol 1977;73:385-389.
15.
Birch RA, Padmanabhan V, Foster DL, Unsworth WP, Robinson JE: Prenatal programming of reproductive neuroendocrine function: fetal androgen exposure produces progressive disruption of reproductive cycles in sheep. Endocrinology 2003;144:1426-1434.
16.
Steckler T, Roberts E, Doop D, Lee T, Padmanabhan V: Developmental programming in sheep: administration of testosterone during 60-90 days of pregnancy reduces breeding success and pregnancy outcome. Theriogenology 2007;67:459-467.
17.
Wood RI, Foster DL: Sexual differentiation of reproductive neuroendocrine function in sheep. Rev Reprod 1998;3:130-140.
18.
Steckler TL, Herkimer C, Dumesic DA, Padmanabhan V: Developmental programming: excess weight gain amplifies the effects of prenatal testosterone excess on reproductive cyclicity - implication for polycystic ovary syndrome. Endocrinology 2009;150:1456-1465.
19.
Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M, Ho SM: Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp 1) correlates with overexpression of Nsbp 1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 2008;149:5922-5931.
20.
Veiga-Lopez A, Steckler TL, Abbott DH, Welch KB, Mohan Kumar PS, Phillips DJ, Refsal K, Padmanabhan V: Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol Reprod 2011;84:87-96.
21.
Arnold AP, Breedlove SM: Organizational and activational effects of sex steroids on brain and behavior: a reanalysis. Horm Behav 1985;19:469-498.
22.
Toran-Allerand CD: Sex steroids and the development of the newborn mouse hypothalamus and preoptic area in vitro: implications for sexual differentiation. Brain Res 1976;106:407-412.
23.
Brooks AN, Thomas GB: Ontogeny and function of the pituitary-gonodal axis during fetal development in sheep. Reprod Domest Anim 1995;30:158-162.
24.
Manikkam M, Thompson RC, Herkimer C, Welch KB, Flak J, Karsch FJ, Padmanabhan V: Developmental programming: impact of prenatal testosterone excess on pre- and postnatal gonadotropin regulation in sheep. Biol Reprod 2008;78:648-660.
25.
Pepe GJ, Billiar RB, Albrecht ED: Regulation of baboon fetal ovarian folliculogenesis by estrogen. Mol Cell Endocrinol 2006;247:41-46.
26.
Abbott DH, Padmanabhan V, Dumesic DA: Contribution of estrogen and androgen to fetal programming of ovarian dysfunction. Reprod Biol Endocrinol 2006;4:17.
27.
Abi-Salloum B, Veiga-Lopez A, Abbott DH, Burant CF, Padmanabhan V: Developmental programming: exposure to testosterone excess disrupts steroidal and metabolic environment in pregnant sheep. Endocrinology 2015;156:2323-2337.
28.
Wood R, Newman S, Lehman M, Foster D: GnRH neurons in the fetal lamb hypothalamus are similar in males and females. Neuroendocrinology 1992;55:427-433.
29.
Brooks A, Hagan D, Sheng C, McNeilly A, Sweeney T: Prenatal gonadotrophins in the sheep. Anim Reprod Sci 1996;42:471-481.
30.
Sawyer HR, Smith P, Heath DA, Juengel JL, McNatty KP: Formation of ovarian follicles during fetal development in sheep. Biol Reprod 2002;66:1134-1150.
31.
McNatty K, Fidler A, Juengel J, Quirke L, Smith P, Heath D, Lundy T, O'Connell A, Tisdall D: Growth and paracrine factors regulating follicular formation and cellular function. Mol Cell Endocrinol 2000;163:11-20.
32.
Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev 2010;5:7.
33.
Desai M, Li T, Ross MG: Fetal hypothalamic neuroprogenitor cell culture: preferential differentiation paths induced by leptin and insulin. Endocrinology 2011;152:3192-3201.
34.
Dubois PM: Ontogenesis of gonadotropic cells. Ann Endocrinol 1990;51:47-53.
35.
Isik S, Ozcan HN, Ozuguz U, Tutuncu YA, Berker D, Alimli AG, Akbaba G, Karademir MA, Guler S: Evaluation of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2011;97:261-269.
36.
Driscoll SG, Benirschke K, Curtis GW: Neonatal deaths among infants of diabetic mothers: postmortem findings in ninety-five infants. Am J Dis Child 1960;100:818-835.
37.
Sir-Petermann T, Maliqueo M, Angel B, Lara H, Perez-Bravo F, Recabarren S: Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002;17:2573-2579.
38.
Cernea M, Lee T, Cheng G, Padmanabhan V, Lehman MN, Coolen LM: Excess prenatal testosterone increases androgen receptor expression in hypothalamic areas of the female sheep brain (abstract). 41st Annu Meet Soc Neurosci, Washington, 2011, vol 499.
39.
Ortega HH, Salvetti NR, Padmanabhan V: Developmental programming: prenatal androgen excess disrupts ovarian steroid receptor balance. Reproduction 2009;137:865-877.
40.
Nada SE, Thompson RC, Padmanabhan V: Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues. Endocrinology 2010;151:5165-5173.
41.
Padmanabhan V, Veiga-Lopez A, Abbott D, Recabarren S, Herkimer C: Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 2010;151:595-605.
42.
Padmanabhan V, Veiga-Lopez A, Herkimer CC, Salloum BA, Moeller J, Beckett E, Sreedharan R: Developmental programming: prenatal and postnatal androgen antagonist and insulin sensitizer interventions prevent advancement of puberty and improve LH surge dynamics in prenatal testosterone-treated sheep. Endocrinology 2015;156:2678-2692.
43.
Veiga-Lopez A, Lee JS, Padmanabhan V: Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep. Endocrinology 2010;151:4007-4017.
44.
Sarma HN, Manikkam M, Herkimer C, Dell'Orco J, Welch KB, Foster DL, Padmanabhan V: Fetal programming: excess prenatal testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating hormone responsiveness, to estradiol negative feedback in the female. Endocrinology 2005;146:4281-4291.
45.
Veiga-Lopez A, Astapova OI, Aizenberg EF, Lee JS, Padmanabhan V: Developmental programming: contribution of prenatal androgen and estrogen to estradiol feedback systems and periovulatory hormonal dynamics in sheep. Biol Reprod 2009;80:718-725.
46.
Foster DL, Jackson LM, Padmanabhan V: Novel concepts about normal sexual differentiation of reproductive neuroendocrine function and the developmental origins of female reproductive dysfunctions: the sheep model. Soc Reprod Fertil Suppl 2007;64:83-107.
47.
Sharma TP, Herkimer C, West C, Ye W, Birch R, Robinson JE, Foster DL, Padmanabhan V: Fetal programming: prenatal androgen disrupts positive feedback actions of estradiol but does not affect timing of puberty in female sheep. Biol Reprod 2002;66:924-933.
48.
Unsworth WP, Taylor JA, Robinson JE: Prenatal programming of reproductive neuroendocrine function: the effect of prenatal androgens on the development of estrogen positive feedback and ovarian cycles in the ewe. Biol Reprod 2005;72:619-627.
49.
Robinson JE, Forsdike RA, Taylor JA: In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology 1999;140:5797-5805.
50.
Jackson LM, Timmer KM, Foster DL: Sexual differentiation of the external genitalia and the timing of puberty in the presence of an antiandrogen in sheep. Endocrinology 2008;149:4200-4208.
51.
Abi Salloum B, Herkimer C, Lee JS, Veiga-Lopez A, Padmanabhan V: Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep. Endocrinology 2012;153:2813-2822.
52.
Goodman RL, Lehman MN: Kisspeptin neurons from mice to men: similarities and differences. Endocrinology 2012;153:5105-5118.
53.
Cheng G, Coolen LM, Padmanabhan V, Goodman RL, Lehman MN: The kisspeptin/neurokinin B/dynorphin (KNDy) cell population of the arcuate nucleus: sex differences and effects of prenatal testosterone in sheep. Endocrinology 2010;151:301-311.
54.
Lehman MN, Coolen LM, Goodman RL: Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology 2010;151:3479-3489.
55.
Ahn T, Fergani C, Coolen L, Padmanabhan V, Lehman M: Prenatal testosterone excess decreases neurokinin 3 receptor immunoreactivity within the arcuate nucleus KNDy cell population. J Neuroendocrinol 2015;27:100-110.
56.
Jackson LM, Mytinger A, Roberts EK, Lee TM, Foster DL, Padmanabhan V, Jansen HT: Developmental programming: postnatal steroids complete prenatal steroid actions to differentially organize the GnRH surge mechanism and reproductive behavior in female sheep. Endocrinology 2013;154:1612-1623.
57.
Cernea M, Phillips R, Padmanabhan V, Coolen LM, Lehman MN: Prenatal testosterone decreases co-expression of insulin receptors in KNDy neurons in adult ewes (abstract). 2nd World Conf Kisspeptin Signaling Brain, Tokyo, 2012, vol 84.
58.
Sliwowska JH, Fergani C, Gawałek M, Skowronska B, Fichna P, Lehman MN: Insulin: its role in the central control of reproduction. Physiol Behav 2014;133:197-206.
59.
Qiu X, Dowling AR, Marino JS, Faulkner LD, Bryant B, Bruning JC, Elias CF, Hill JW: Delayed puberty but normal fertility in mice with selective deletion of insulin receptors from Kiss1 cells. Endocrinology 2013;154:1337-1348.
60.
Robinson JE, Hastie PM, Shah A, Smith A, Evans NP: Developmental programming: prenatal androgen exposure alters the gonadotroph population of the ovine pituitary gland. J Neuroendocrinol 2012;24:434-442.
61.
Buggs C, Weinberg F, Kim E, Wolfe A, Radovick S, Wondisford F: Insulin augments GnRH-stimulated LHbeta gene expression by Egr-1. Mol Cell Endocrinol 2006;249:99-106.
62.
Soldani R, Cagnacci A, Yen SS: Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endocrinol 1994;131:641-645.
63.
Steckler T, Wang J, Bartol FF, Roy SK, Padmanabhan V: Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 2005;146:3185-3193.
64.
West C, Foster DL, Evans NP, Robinson J, Padmanabhan V: Intra-follicular activin availability is altered in prenatally androgenized lambs. Mol Cell Endocrinol 2001;185:51-59.
65.
Escobar M, Vázquez-Nin G, Echeverría O: Follicular cells; in Vázquez-Nin G, Escobar M, De Felici M, Echeverría O, Klinger F (eds): Cell Death in Mammalian Ovary. Dordrecht, Springer, 2011, pp 185-200.
66.
McLaughlin EA, McIver SC: Awakening the oocyte: controlling primordial follicle development. Reproduction 2009;137:1-11.
67.
Fortune J: The early stages of follicular development: activation of primordial follicles and growth of preantral follicles. Anim Reprod Sci 2003;78:135-163.
68.
Skinner MK: Regulation of primordial follicle assembly and development. Hum Reprod Update 2005;11:461-471.
69.
Gougeon A: Dynamics of human follicular growth: morphologic, dynamic, and functional aspects; in Leung PCK, Adashi EY (eds): The Ovary. San Diego, Elsevier Academic Press, 2004, vol 2, pp 25-43.
70.
Sobinoff AP, Sutherland JM, McLaughlin EA: Intracellular signalling during female gametogenesis. Mol Hum Reprod 2013;19:265-278.
71.
Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA: Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003;301:215-218.
72.
Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, Du C, Tang W, Hamalainen T, Peng SL, et al: Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 2008;319:611-613.
73.
Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP: Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999;140:5789-5796.
74.
Yang J-L, Zhang C-P, Li L, Huang L, Ji S-Y, Lu C-L, Fan C-H, Cai H, Ren Y, Hu Z-Y: Testosterone induces redistribution of forkhead box-3a and down-regulation of growth and differentiation factor 9 messenger ribonucleic acid expression at early stage of mouse folliculogenesis. Endocrinology 2010;151:774-782.
75.
Lebbe M, Woodruff TK: Involvement of androgens in ovarian health and disease. Mol Hum Reprod 2013;19:828-837.
76.
Pru JK, Tilly JL: Programmed cell death in the ovary: insights and future prospects using genetic technologies. Mol Endocrinol 2001;15:845-853.
77.
Hubmacher D, Tiedemann K, Reinhardt DP: Fibrillins: from biogenesis of microfibrils to signaling functions. Curr Top Dev Biol 2006;75:93-123.
78.
Jordan CD, Bohling SD, Charbonneau NL, Sakai LY: Fibrillins in adult human ovary and polycystic ovary syndrome: is fibrillin-3 affected in PCOS? J Histochem Cytochem 2010;58:903-915.
79.
Hatzirodos N, Bayne RA, Irving-Rodgers HF, Hummitzsch K, Sabatier L, Lee S, Bonner W, Gibson MA, Rainey WE, Carr BR: Linkage of regulators of TGF-β activity in the fetal ovary to polycystic ovary syndrome. FASEB J 2011;25:2256-2265.
80.
Veiga-Lopez A, Ye W, Padmanabhan V: Developmental programming: prenatal testosterone excess disrupts anti-Müllerian hormone expression in preantral and antral follicles. Fertil Steril 2012;97:748-756.
81.
Salvetti NR, Ortega HH, Veiga-Lopez A, Padmanabhan V: Developmental programming: impact of prenatal testosterone excess on ovarian cell proliferation and apoptotic factors in sheep. Biol Reprod 2012;87:22.
82.
Teixeira Filho FL, Baracat EC, Lee TH, Suh CS, Matsui M, Chang RJ, Shimasaki S, Erickson GF: Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1337-1344.
83.
Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM: Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 1996;383:531-535.
84.
Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS: The role of TGF-β in polycystic ovary syndrome. Reprod Sci 2014;21:20-31.
85.
Knight PG, Satchell L, Glister C: Intra-ovarian roles of activins and inhibins. Mol Cell Endocrinol 2012;359:53-65.
86.
Liu Z, Castrillon DH, Zhou W, Richards JS: FOXO1/3 depletion in granulosa cells alters follicle growth, death and regulation of pituitary FSH. Mol Endocrinol 2013;27:238-252.
87.
Mazerbourg S, Bondy CA, Zhou J, Monget P: The insulin-like growth factor system: a key determinant role in the growth and selection of ovarian follicles? A comparative species study. Reprod Domest Anim 2003;38:247-258.
88.
Visser JA, Themmen AP: Role of anti-Mullerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity. Mol Cell Endocrinol 2014;382:460-465.
89.
Mather JP, Moore A, Li RH: Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Exp Biol Med 1997;215:209-222.
90.
Palin M-F, Bordignon VV, Murphy BD: Adiponectin and the control of female reproductive functions. Vitam Horm 2012;90:239-287.
91.
Maillard V, Uzbekova S, Guignot F, Perreau C, Ramé C, Coyral-Castel S, Dupont J: Effect of adiponectin on bovine granulosa cell steroidogenesis, oocyte maturation and embryo development. Reprod Biol Endocrinol 2010;8:23.
92.
Dumesic DA, Padmanabhan V, Abbott DH: Polycystic ovary syndrome and oocyte developmental competence. Obstet Gynecol Surv 2008;63:39-48.
93.
Dumesic DA, Richards JS: Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril 2013;100:23-38.
94.
Kwintkiewicz J, Giudice LC: The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin Reprod Med 2009;27:43-51.
95.
McFee RM, Rozell TG, Crupp AS: The balance between proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development. Cell Tissue Res 2012;349:635-647.
96.
Dumesic DA, Abbott DH, Padmanabhan V: Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007;8:127-141.
97.
Padmanabhan V, Salvetti NR, Matiller V, Ortega HH: Developmental programming: prenatal steroid excess disrupts key members of intraovarian steroidogenic pathway in sheep. Endocrinology 2014;155:3649-3660.
98.
Hough D, Cloete S, Storbeck K, Swart A, Swart P: Cortisol production in sheep is influenced by the functional expression of two cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17) isoforms. J Anim Sci 2013;91:1193-1206.
99.
Ortega HH, Rey F, Velazquez MM, Padmanabhan V: Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep. Biol Reprod 2010;82:1065-1075.
100.
Dumesic DA, Schramm RD, Peterson E, Paprocki AM, Zhou R, Abbott DH: Impaired developmental competence of oocytes in adult prenatally androgenized female rhesus monkeys undergoing gonadotropin stimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87:1111-1119.
101.
Dumesic DA, Abbott DH: Implications of polycystic ovary syndrome on oocyte development. Semin Reprod Med 2008;26:53-61.
102.
Manikkam M, Crespi EJ, Doop DD, Herkimer C, Lee JS, Yu S, Brown MB, Foster DL, Padmanabhan V: Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology 2004;145:790-798.
103.
Boney CM, Verma A, Tucker R, Vohr BR: Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005;115:e290-e296.
104.
Dulloo AG: Thrifty energy metabolism in catch-up growth trajectories to insulin and leptin resistance. Best Pract Res Clin Endocrinol Metab 2008;22:155-171.
105.
Crespi EJ, Steckler TL, Mohan Kumar PS, Padmanabhan V: Prenatal exposure to excess testosterone modifies the developmental trajectory of the insulin-like growth factor system in female sheep. J Physiol 2006;572:119-130.
106.
King AJ, Olivier NB, Mohan Kumar PS, Lee JS, Padmanabhan V, Fink GD: Hypertension caused by prenatal testosterone excess in female sheep. Am J Physiol Endocrinol Metab 2007;292:e1837-e1841.
107.
Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE: Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab 2008;295:e262-e268.
108.
Zhou R, Bird IM, Dumesic DA, Abbott DH: Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:6630-6637.
109.
De Haan K, Berger L, Bechtel P, Kesler D, McKeith F, Thomas D: Effect of prenatal testosterone treatment on nitrogen utilization and endocrine status of ewe lambs. J Anim Sci 1990;68:4100-4108.
110.
Hansen L, Drackley J, Berger L, Grum D: Prenatal androgenization of lambs. I. Alterations of growth, carcass characteristics, and metabolites in blood. J Anim Sci 1995;73:1694-1700.
111.
Recabarren SE, Padmanabhan V, Codner E, Lobos A, Durán C, Vidal M, Foster DL, Sir-Petermann T: Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metab 2005;289:e801-e806.
112.
Veiga-Lopez A, Moeller J, Patel D, Ye W, Pease A, Kinns J, Padmanabhan V: Developmental programming: impact of prenatal testosterone excess on insulin sensitivity, adiposity, and free fatty acid profile in postpubertal female sheep. Endocrinology 2013;154:1731-1742.
113.
Corbould A, Kim Y-B, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A: Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005;288:e1047-e1054.
114.
Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E: Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:e392-e399.
115.
Glintborg D, Højlund K, Andersen NR, Hansen BF, Beck-Nielsen H, Wojtaszewski JF: Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab 2008;93:3618-3626.
116.
Cortón M, Botella-Carretero JI, Benguria A, Villuendas G, Zaballos A, San Millán JL, Escobar-Morreale HF, Peral B: Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:328-337.
117.
Seow K-M, Juan C-C, Hsu Y-P, Hwang J-L, Huang L-W, Ho L-T: Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery. Hum Reprod 2007;22:1003-1010.
118.
Beckett EM, Astapova O, Steckler TL, Veiga-Lopez A, Padmanabhan V: Developmental programming: impact of testosterone on placental differentiation. Reproduction 2014;148:199-209.
119.
Godfrey KM, Barker DJ: Fetal programming and adult health. Public Health Nutr 2001;4:611-624.
120.
Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000;106:473-481.
121.
Antuna-Puente B, Feve B, Fellahi S, Bastard J-P: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11.
122.
Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
123.
Yudkin JS, Stehouwer C, Emeis J, Coppack S: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978.
124.
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JSE, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28-38.
125.
Padmanabhan V, Veiga-Lopez A: Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol 2013;373:8-20.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.